[NFS-01] Neuroscience Frontier Symposium 01
New approaches aimed for the development of disease modifying therapies of Alzheimer's disease and other dementia diseases

[NFS-01-1] The pathological link of glia activation with amyloid clearance in Alzheimer disease

^○Taisuke Tomita (Laboratory of Neuropathology and Neuroscience, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Japan)

Alzheimer's disease (AD) is the most common neurodegenerative disorder and affects over 40 million patients worldwide, but no causative or preventive treatment is currently available. However, recent researches have gradually elucidated new pathogenesis of AD and other dementia disease, and researches linking to disease modification therapies (DMTs) are also progressing. In this symposium, we introduce cutting-edge approaches for DMTs development of AD and other demnetia diseases, and discuss their translational possibilities and issues to be resolved.

Education/Training
2000 Ph.D. (Pharmaceutical Science) from The University of Tokyo, Tokyo, Japan
2004-2005 Visiting Scientist at Washington University in St. Louis
Positions
1997-2003 Assistant Professor in Laboratory of Neuropathology and Neuroscience, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Japan
2003-2006 Lecturer in Laboratory of Neuropathology and Neuroscience, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Japan
2006-2014 Associate Professor in Laboratory of Neuropathology and Neuroscience, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Japan
2014-present Professor in Laboratory of Neuropathology and Neuroscience, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Japan
2017-present Adjunct Professor in Laboratory of Brain and Neurological Disorders, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Japan